Pharmaceutical companies have been spending a lot of money on new cancer treatments, but the results have been less than stellar, says Robert Langreth on Forbes' Treatments blog. Pfizer, for example, has been spending a lot of money to develop a cancer drug that, in testing, helps only five percent of lung cancer patients with a particular tumor mutation.